E-viri
Recenzirano
Odprti dostop
-
TRABERT, Britton; NESS, Roberta B; RISCH, Harvey A; ROSSING, Mary Anne; DOHERTY, Jennifer A; GOODMAN, Marc T; LURIE, Galina; KJAER, Susanne K; HOGDALL, Estrid; JENSEN, Allan; CRAMER, Daniel W; TERRY, Kathryn L; LO-CIGANIC, Wei-Hsuan; VITONIS, Allison; BANDERA, Elisa V; OLSON, Sara; KING, Melony G; CHANDRAN, Urmila; ANTON-CULVER, Hoda; ZIOGAS, Argyrios; MENON, Usha; GAYTHER, Simon A; RAMUS, Susan J; MURPHY, Megan A; GENTRY-MAHARAJ, Aleksandra; WU, Anna H; PEARCE, Celeste Leigh; PIKE, Malcolm C; BERCHUCK, Andrew; SCHILDKRAUT, Joellen M; WENTZENSEN, Nicolas; GOODE, Ellen L; POOLE, Elizabeth M; BRINTON, Louise A; WEBB, Penelope M; NAGLE, Christina M; JORDAN, Susan J
JNCI : Journal of the National Cancer Institute, 02/2014, Letnik: 106, Številka: 2Journal Article
Regular aspirin use is associated with reduced risk of several malignancies. Epidemiologic studies analyzing aspirin, nonaspirin nonsteroidal anti-inflammatory drug (NSAID), and acetaminophen use and ovarian cancer risk have been inconclusive. We analyzed pooled data from 12 population-based case-control studies of ovarian cancer, including 7776 case patients and 11843 control subjects accrued between 1992 and 2007. Odds ratios (ORs) for associations of medication use with invasive epithelial ovarian cancer were estimated in individual studies using logistic regression and combined using random effects meta-analysis. Associations between frequency, dose, and duration of analgesic use and risk of ovarian cancer were also assessed. All statistical tests were two-sided. Aspirin use was associated with a reduced risk of ovarian cancer (OR = 0.91; 95% confidence interval CI = 0.84 to 0.99). Results were similar but not statistically significant for nonaspirin NSAIDs, and there was no association with acetaminophen. In seven studies with frequency data, the reduced risk was strongest among daily aspirin users (OR = 0.80; 95% CI = 0.67 to 0.96). In three studies with dose information, the reduced risk was strongest among users of low dose (<100 mg) aspirin (OR = 0.66; 95% CI = 0.53 to 0.83), whereas for nonaspirin NSAIDs, the reduced risk was strongest for high dose (≥500 mg) usage (OR = 0.76; 95% CI = 0.64 to 0.91). Aspirin use was associated with a reduced risk of ovarian cancer, especially among daily users of low-dose aspirin. These findings suggest that the same aspirin regimen proven to protect against cardiovascular events and several cancers could reduce the risk of ovarian cancer 20% to 34% depending on frequency and dose of use.
Avtor
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.